TN2011000319A1 - Substituted quinazoline compounds - Google Patents
Substituted quinazoline compoundsInfo
- Publication number
- TN2011000319A1 TN2011000319A1 TN2011000319A TN2011000319A TN2011000319A1 TN 2011000319 A1 TN2011000319 A1 TN 2011000319A1 TN 2011000319 A TN2011000319 A TN 2011000319A TN 2011000319 A TN2011000319 A TN 2011000319A TN 2011000319 A1 TN2011000319 A1 TN 2011000319A1
- Authority
- TN
- Tunisia
- Prior art keywords
- methods
- kinase
- diseases
- ameliorating
- treating
- Prior art date
Links
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 6
- 108091000080 Phosphotransferase Proteins 0.000 abstract 3
- 230000001404 mediated effect Effects 0.000 abstract 3
- 102000020233 phosphotransferase Human genes 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08360043 | 2008-12-29 | ||
| PCT/EP2009/067494 WO2010076238A1 (en) | 2008-12-29 | 2009-12-18 | Substituted quinazoline compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2011000319A1 true TN2011000319A1 (en) | 2012-12-17 |
Family
ID=41735344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TN2011000319A TN2011000319A1 (en) | 2008-12-29 | 2011-06-27 | Substituted quinazoline compounds |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8389530B2 (enExample) |
| EP (1) | EP2381943A1 (enExample) |
| JP (1) | JP2012514020A (enExample) |
| KR (1) | KR20110120878A (enExample) |
| CN (1) | CN102333533A (enExample) |
| AU (1) | AU2009334869A1 (enExample) |
| BR (1) | BRPI0924067A2 (enExample) |
| CA (1) | CA2748319A1 (enExample) |
| CO (1) | CO6390105A2 (enExample) |
| CR (1) | CR20110368A (enExample) |
| DO (1) | DOP2011000209A (enExample) |
| EA (1) | EA019110B1 (enExample) |
| EC (1) | ECSP11011204A (enExample) |
| IL (1) | IL213742A0 (enExample) |
| MA (1) | MA32968B1 (enExample) |
| MX (1) | MX2011007064A (enExample) |
| NI (1) | NI201100134A (enExample) |
| NZ (1) | NZ593949A (enExample) |
| PE (1) | PE20120424A1 (enExample) |
| SG (1) | SG172415A1 (enExample) |
| TN (1) | TN2011000319A1 (enExample) |
| WO (1) | WO2010076238A1 (enExample) |
| ZA (1) | ZA201104777B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR081960A1 (es) | 2010-06-22 | 2012-10-31 | Fovea Pharmaceuticals Sa | Compuestos heterociclicos, su preparacion y su aplicacion terapeutica |
| US8802697B2 (en) | 2012-07-11 | 2014-08-12 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| AU2014339972B9 (en) | 2013-10-25 | 2019-05-30 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
| KR101715448B1 (ko) * | 2014-07-16 | 2017-03-20 | 주식회사 큐리언트 | 염증성 질환 치료용 화합물 |
| SG11201705192PA (en) | 2014-12-24 | 2017-07-28 | Gilead Sciences Inc | Fused pyrimidine compounds for the treatment of hiv |
| TWI770552B (zh) | 2014-12-24 | 2022-07-11 | 美商基利科學股份有限公司 | 喹唑啉化合物 |
| ES2705709T3 (es) | 2014-12-24 | 2019-03-26 | Gilead Sciences Inc | Compuestos de isoquinolina para el tratamiento del VIH |
| CN112239459B (zh) * | 2019-07-19 | 2021-11-26 | 中国科学院上海药物研究所 | 稠环嘧啶氨基化合物、其制备方法、药物组合物及应用 |
| CN115916759B (zh) * | 2020-06-19 | 2025-07-15 | 泰州红云制药有限公司 | 取代喹唑啉类化合物、其制备方法、药物组合及应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0015718A (pt) | 1999-11-22 | 2002-07-23 | Warner Lambert Co | Quinazolinas e seu uso para inibição de enzimas de cinase dependente de ciclina |
| WO2004065378A1 (en) | 2003-01-17 | 2004-08-05 | Warner-Lambert Company Llc | 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation |
| CA2542329A1 (en) | 2003-10-16 | 2005-04-28 | Chiron Corporation | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer |
| NZ551027A (en) | 2004-04-08 | 2011-01-28 | Targegen Inc | Benzotriazine inhibitors of kinases |
| JP5275628B2 (ja) | 2004-08-25 | 2013-08-28 | ターゲジェン インコーポレーティッド | 複素環式化合物および使用方法 |
| US20070054916A1 (en) * | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| CN101155799A (zh) | 2005-03-16 | 2008-04-02 | 塔格根公司 | 嘧啶化合物和使用方法 |
| US7906522B2 (en) * | 2005-04-28 | 2011-03-15 | Kyowa Hakko Kirin Co., Ltd | 2-aminoquinazoline derivatives |
| AU2006254825A1 (en) | 2005-06-08 | 2006-12-14 | Targegen, Inc. | Methods and compositions for the treatment of ocular disorders |
| AR060358A1 (es) * | 2006-04-06 | 2008-06-11 | Novartis Vaccines & Diagnostic | Quinazolinas para la inhibicion de pdk 1 |
| JP2010514693A (ja) * | 2006-12-22 | 2010-05-06 | ノバルティス アーゲー | Ｐｄｋ１阻害のためのキナゾリン |
-
2009
- 2009-12-18 PE PE2011001296A patent/PE20120424A1/es not_active Application Discontinuation
- 2009-12-18 WO PCT/EP2009/067494 patent/WO2010076238A1/en not_active Ceased
- 2009-12-18 MX MX2011007064A patent/MX2011007064A/es active IP Right Grant
- 2009-12-18 SG SG2011047339A patent/SG172415A1/en unknown
- 2009-12-18 CN CN2009801575427A patent/CN102333533A/zh active Pending
- 2009-12-18 MA MA34018A patent/MA32968B1/fr unknown
- 2009-12-18 NZ NZ593949A patent/NZ593949A/xx not_active IP Right Cessation
- 2009-12-18 JP JP2011544017A patent/JP2012514020A/ja active Pending
- 2009-12-18 EA EA201101012A patent/EA019110B1/ru not_active IP Right Cessation
- 2009-12-18 KR KR1020117017495A patent/KR20110120878A/ko not_active Withdrawn
- 2009-12-18 CA CA2748319A patent/CA2748319A1/en not_active Abandoned
- 2009-12-18 AU AU2009334869A patent/AU2009334869A1/en not_active Abandoned
- 2009-12-18 BR BRPI0924067A patent/BRPI0924067A2/pt not_active IP Right Cessation
- 2009-12-18 EP EP09799340A patent/EP2381943A1/en not_active Withdrawn
- 2009-12-18 US US13/142,333 patent/US8389530B2/en not_active Expired - Fee Related
-
2011
- 2011-06-23 IL IL213742A patent/IL213742A0/en unknown
- 2011-06-27 TN TN2011000319A patent/TN2011000319A1/fr unknown
- 2011-06-27 CR CR20110368A patent/CR20110368A/es not_active Application Discontinuation
- 2011-06-28 ZA ZA2011/04777A patent/ZA201104777B/en unknown
- 2011-06-29 DO DO2011000209A patent/DOP2011000209A/es unknown
- 2011-06-29 CO CO11081323A patent/CO6390105A2/es not_active Application Discontinuation
- 2011-06-29 NI NI201100134A patent/NI201100134A/es unknown
- 2011-07-14 EC EC2011011204A patent/ECSP11011204A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009334869A1 (en) | 2011-07-14 |
| BRPI0924067A2 (pt) | 2016-01-26 |
| DOP2011000209A (es) | 2011-09-30 |
| MX2011007064A (es) | 2012-01-20 |
| CR20110368A (es) | 2011-12-02 |
| EA019110B1 (ru) | 2014-01-30 |
| NZ593949A (en) | 2013-08-30 |
| PE20120424A1 (es) | 2012-05-04 |
| IL213742A0 (en) | 2011-07-31 |
| JP2012514020A (ja) | 2012-06-21 |
| WO2010076238A1 (en) | 2010-07-08 |
| ZA201104777B (en) | 2012-03-28 |
| EP2381943A1 (en) | 2011-11-02 |
| KR20110120878A (ko) | 2011-11-04 |
| AU2009334869A2 (en) | 2011-09-29 |
| EA201101012A1 (ru) | 2012-01-30 |
| ECSP11011204A (es) | 2011-10-31 |
| NI201100134A (es) | 2012-03-06 |
| US8389530B2 (en) | 2013-03-05 |
| US20120004210A1 (en) | 2012-01-05 |
| CA2748319A1 (en) | 2010-07-08 |
| SG172415A1 (en) | 2011-07-28 |
| CO6390105A2 (es) | 2012-02-29 |
| MA32968B1 (fr) | 2012-01-02 |
| CN102333533A (zh) | 2012-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2011000319A1 (en) | Substituted quinazoline compounds | |
| TN2011000379A1 (en) | [1, 2, 4] triazolo [1,5-a ] pyridines as kinase inhibitors | |
| NZ605022A (en) | Heterocyclic compounds, their preparation and their therapeutic application | |
| SG194718A1 (en) | Novel compounds as modulators of protein kinases | |
| PH12015500248A1 (en) | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses | |
| IN2012DN02469A (enExample) | ||
| AU2012277802A8 (en) | Novel inhibitor compounds of phosphodiesterase type 10A | |
| WO2009011850A3 (en) | Novel therapeutic compounds | |
| AU2016219704A1 (en) | Anti-Notch1 antibodies | |
| HK1199643A1 (en) | Oxazolidin- 2 -one compounds and uses thereof as pi3ks inhibitors | |
| MX2009011951A (es) | Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr. | |
| MX2009003724A (es) | Derivados de 2-aminocarbonil-piridina. | |
| WO2012125408A8 (en) | Pegylated apelin and uses thereof | |
| MX2009011952A (es) | Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr. | |
| WO2012080497A3 (en) | Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases | |
| MX340536B (es) | Terapia direccionada al receptor del factor de crecimiento epidermico (egfr). | |
| WO2011041325A3 (en) | Methods and compositions for the treatment of viral disorders | |
| WO2010126609A3 (en) | Treatment of diseases with altered smooth muscle contractility | |
| MX2013006118A (es) | Tratamiento de inflamacion cronica con un derivado de 1, 2, 4-triazolo [1,5a] piridina. |